| Neha A Sathe, MD | |
|
325 9th Ave, Seattle, WA 98104-2420 | |
| (206) 520-5000 | |
| Not Available |
| Full Name | Neha A Sathe |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 325 9th Ave, Seattle, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346651114 | NPI | - | NPPES |
| 1346651114 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD60839327 (Washington) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD60839327 (Washington) | Primary |
| Entity Name | The Association Of University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
Civilian deaths have risen dramatically in Iraq since the country was invaded in March 2003, according to a survey conducted by researchers from the Johns Hopkins Bloomberg School of Public Health, Columbia University School of Nursing and Al-Mustansiriya University in Baghdad.
A DNA-sensing enzyme forms droplets that act as tiny bioreactors creating molecules to stimulate innate immunity – the body's first response to infection, UT Southwestern researchers report. The work, reported today in the journal Science, could lead to novel treatments for infections, autoimmune disease, and cancer.
A new artificial pancreas system that uses advanced control algorithms to automatically monitor and regulate blood glucose levels was more effective than existing treatments at controlling blood glucose levels in people with type 1 diabetes, according to a multicenter randomized clinical trial based partly at the Icahn School of Medicine at Mount Sinai.
President Donald Trump told the American people this week that convalescent plasma is a potential new treatment for COVID-19.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Neha A Sathe, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 520-5700 | Neha A Sathe, MD 325 9th Ave, Seattle, WA 98104-2420 Ph: (206) 520-5000 |
News Archive
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.
Civilian deaths have risen dramatically in Iraq since the country was invaded in March 2003, according to a survey conducted by researchers from the Johns Hopkins Bloomberg School of Public Health, Columbia University School of Nursing and Al-Mustansiriya University in Baghdad.
A DNA-sensing enzyme forms droplets that act as tiny bioreactors creating molecules to stimulate innate immunity – the body's first response to infection, UT Southwestern researchers report. The work, reported today in the journal Science, could lead to novel treatments for infections, autoimmune disease, and cancer.
A new artificial pancreas system that uses advanced control algorithms to automatically monitor and regulate blood glucose levels was more effective than existing treatments at controlling blood glucose levels in people with type 1 diabetes, according to a multicenter randomized clinical trial based partly at the Icahn School of Medicine at Mount Sinai.
President Donald Trump told the American people this week that convalescent plasma is a potential new treatment for COVID-19.
› Verified 9 days ago
Sandhya Ramanathan Panch, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Stephen A Lopez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 925 Seneca St, Seattle, WA 98101 Phone: 206-341-0860 | |
Dr. Susan Hunt, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Uwmc Department Of Medicine, Box 356429, Seattle, WA 98195 Phone: 206-221-7993 Fax: 206-221-8732 | |
Timothy William Menza, MD, PHD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Dr. Vinay Gupta, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-223-6980 Fax: 206-223-6982 | |
Dr. Maria Ann Corcorran, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-520-5000 | |
Vyshak Alva Venur, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5700 |